首页> 外文期刊>Platelets >Inhibition of gamma-thrombin-induced human platelet aggregation by histone H1subtypes and H1.3 fragments.
【24h】

Inhibition of gamma-thrombin-induced human platelet aggregation by histone H1subtypes and H1.3 fragments.

机译:组蛋白H1亚型和H1.3片段对γ-凝血酶诱导的人血小板聚集的抑制作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Human platelets are differentially activated by varying concentrations of alpha-thrombin or by beta- and gamma-thrombin via three thrombin receptors, PAR-1, PAR-4 and GPIbalpha.It is likely that the development of a normal or abnormal hemostatic event in humans is dictated, in part, by the selective activation of these receptors. The ability to differentially inhibit these thrombin receptors could, therefore, have clinical significance. We have previously demonstrated that histone H1 selectively inhibits the PAR-4 receptor. In the current study we investigated whether five subtypes of the H1 molecule or fragments of the H1.3 subtype differentially inhibited the PAR-4 receptor. PAR-4 inhibition by all H1 subtypes was saturated at 1 uM with no statistical difference observed with the five H1 subtypes tested. Of the five fragments generated from the H1.3 molecule only one had significant inhibitory activity against PAR-4. The C-terminal fragment, N.1, generated by the proteolysis of the parent molecule by Asp-N endoproteinase (Aeromonas proteolytica) at the single aspartate residue, showed the same level of PAR-4 inhibition as the intact H1.3 at 1 uM concentrations. Removal of two N-terminal amino acids (Asp-Val as determined by MALDI analysis) from the N.1 fragment further enhanced its inhibitory activity. These studies may help to develop specific drugs to differentially inhibit the platelet thrombin receptors.
机译:人类血小板可通过三种凝血酶受体PAR-1,PAR-4和GPIbalpha的不同浓度的α-凝血酶或β-和γ-凝血酶被不同程度地激活,这可能是人类正常或异常止血事件的发展部分地取决于这些受体的选择性活化。因此,差异抑制这些凝血酶受体的能力可能具有临床意义。先前我们已经证明,组蛋白H1选择性抑制PAR-4受体。在当前的研究中,我们调查了H1分子的五个亚型或H1.3亚型的片段是否差异抑制PAR-4受体。所有H1亚型对PAR-4的抑制均在1 uM时达到饱和,与所测试的5种H1亚型均无统计学差异。从H1.3分子产生的五个片段中,只有一个具有对PAR-4的显着抑制活性。 Asp-N内蛋白酶(Aeromonas proteolytica)在单个天冬氨酸残基处对母体分子进行蛋白水解而产生的C端片段N.1,在PAR-1抑制水平与完整H1.3(1)相同uM浓度。从N.1片段中去除两个N末端氨基酸(通过MALDI分析确定的Asp-Val)进一步增强了其抑制活性。这些研究可能有助于开发特异性抑制血小板凝血酶受体的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号